Revelation Biosciences, Inc. (REVB) Income Statement Analysis

See more : Affle (India) Limited (AFFLE.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Revelation Biosciences, Inc. (REVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revelation Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Bruush Oral Care Inc. (BRSHW) Income Statement Analysis – Financial Results
Yuhan Corporation (000105.KS) Income Statement Analysis – Financial Results
China Renewable Energy Investment Limited (0987.HK) Income Statement Analysis – Financial Results
Cactus Acquisition Corp. 1 Limited (CCTSU) Income Statement Analysis – Financial Results
Nova Cannabis Inc. (NVACF) Income Statement Analysis – Financial Results

Revelation Biosciences, Inc. (REVB)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.revbiosciences.com

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Metric	2023	2022	2021	2020	2019
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	25.05K	40.01K	69.17K	0.00	0.00
Gross Profit	-25.05K	-40.01K	-69.17K	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	4.15M	5.38M	6.91M	2.56M	0.00
General & Administrative	4.51M	5.49M	5.04M	1.23M	0.00
Selling & Marketing	0.00	0.00	0.00	144.26K	0.00
SG&A	4.51M	5.49M	5.04M	145.49K	3.64K
Other Expenses	0.00	34.96K	-36.35K	0.00	0.00
Operating Expenses	8.66M	10.86M	11.95M	145.49K	3.64K
Cost & Expenses	8.66M	10.86M	11.95M	145.49K	3.64K
Interest Income	0.00	0.00	0.00	10.92K	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	25.05K	40.01K	69.17K	3.80M	171.86K
EBITDA	-95.21K	-10.84M	-11.93M	-145.49K	-3.64K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-8.66M	-10.86M	-11.95M	-145.49K	-3.64K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	8.54M	34.96K	-36.35K	-1.49M	2.00
Income Before Tax	-120.25K	-10.83M	-11.99M	-1.63M	-3.64K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-34.96K	-219.78K	-3.80K	-171.86K
Net Income	-120.25K	-10.79M	-11.99M	-1.63M	-3.64K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.53	-600.77	-1.28K	-188.18	-0.42
EPS Diluted	-0.53	-600.77	-1.28K	-188.18	-0.42
Weighted Avg Shares Out	228.00K	17.97K	9.40K	8.66K	8.66K
Weighted Avg Shares Out (Dil)	228.64K	17.97K	9.40K	8.66K	8.66K

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

December 3, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $REVB #REVB--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive...

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

December 2, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food...

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

November 12, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

November 8, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the...

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

September 24, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent...

How an Election Impacts Penny Stocks

June 25, 2024pennystocks.com

Elections can significantly influence financial markets, including the domain of penny stocks. Penny stocks, often traded below five dollars per share, present a unique opportunity for investors aiming for substantial gains through small initial investments.